Although the survival rate has been improved since the introduction of third-generation anti-neoplastic agents and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, lung cancer is still the leading cause of cancer deaths in the world [1], [2], [3], [4], [5]. This evidence concerns the gene EGFR and lung cancer.